Treatment of coronary in-stent restenosis: a systematic review

J 2018

Treatment of coronary in-stent restenosis: a systematic review

PLEVA, Leos, Pavel KUKLA a Ota HLINOMAZ

Základní údaje

Originální název

Treatment of coronary in-stent restenosis: a systematic review

Autoři

PLEVA, Leos (203 Česká republika, garant), Pavel KUKLA (203 Česká republika) a Ota HLINOMAZ (203 Česká republika, domácí)

Vydání

Journal of Geriatric Cardiology, Beijing, Science Press, 2018, 1671-5411

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Čína

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.763

Kód RIV

RIV/00216224:14110/18:00104044

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.11909/j.issn.1671-5411.2018.02.007

UT WoS

000429624200007

Klíčová slova anglicky

Drug-eluting balloon; Drug-eluting stent; In-stent restenosis

Štítky

14110115, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 11. 2. 2019 15:38, Soňa Böhmová

Anotace

V originále

Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. ISR after coronary angioplasty is currently one of the main limitations of this method, leading to the recurrence of exertional angina pectoris or acute coronary syndromes. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%-10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. We undertook a systematic review of the pathophysiology, diagnostics and treatment options for BMS- and DES-ISR. We discuss recent randomised studies, comparing different DES or DEB used for BMS or DES-ISR treatment, as well as the use of new biovascular scafolds and the topic of scafold restenosis.

Citovat

PLEVA, Leos, Pavel KUKLA a Ota HLINOMAZ. Treatment of coronary in-stent restenosis: a systematic review. Journal of Geriatric Cardiology. Beijing: Science Press, 2018, roč. 15, č. 2, s. 173-184. ISSN 1671-5411. Dostupné z: https://dx.doi.org/10.11909/j.issn.1671-5411.2018.02.007.

@article{1449697,
   author = {Pleva, Leos and Kukla, Pavel and Hlinomaz, Ota},
   article_location = {Beijing},
   article_number = {2},
   doi = {http://dx.doi.org/10.11909/j.issn.1671-5411.2018.02.007},
   keywords = {Drug-eluting balloon; Drug-eluting stent; In-stent restenosis},
   language = {eng},
   issn = {1671-5411},
   journal = {Journal of Geriatric Cardiology},
   title = {Treatment of coronary in-stent restenosis: a systematic review},
   volume = {15},
   year = {2018}
}

TY  - JOUR
ID  - 1449697
AU  - Pleva, Leos - Kukla, Pavel - Hlinomaz, Ota
PY  - 2018
TI  - Treatment of coronary in-stent restenosis: a systematic review
JF  - Journal of Geriatric Cardiology
VL  - 15
IS  - 2
SP  - 173-184
EP  - 173-184
PB  - Science Press
SN  - 16715411
KW  - Drug-eluting balloon
KW  - Drug-eluting stent
KW  - In-stent restenosis
N2  - Coronary stent implantation has significantly improved percutaneous coronary intervention and enabled the management of early complications of plain balloon angioplasty. However, a new complication has accompanied these improvements: in-stent restenosis (ISR) arising from neointimal hyperplasia. ISR after coronary angioplasty is currently one of the main limitations of this method, leading to the recurrence of exertional angina pectoris or acute coronary syndromes. The clinical incidence of ISR after bare-metal stent (BMS) implantation is approximately 20%-35%. The use of drug-eluting stents (DES) has led to a further decrease in the occurrence of ISR to 5%-10%. Evidence resulting from controlled clinical studies suggests that DES and drug-eluting balloon catheters (DEB) provide the best clinical and angiographic results in the treatment of ISR. We undertook a systematic review of the pathophysiology, diagnostics and treatment options for BMS- and DES-ISR. We discuss recent randomised studies, comparing different DES or DEB used for BMS or DES-ISR treatment, as well as the use of new biovascular scafolds and the topic of scafold restenosis.
ER  -

PLEVA, Leos, Pavel KUKLA a Ota HLINOMAZ. Treatment of coronary in-stent restenosis: a systematic review. \textit{Journal of Geriatric Cardiology}. Beijing: Science Press, 2018, roč.~15, č.~2, s.~173-184. ISSN~1671-5411. Dostupné z: https://dx.doi.org/10.11909/j.issn.1671-5411.2018.02.007.

Podrobný výpis o publikaci